Cargando…

iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors

BACKGROUND: Dozens of transplants generated from pluripotent stem cells are currently in clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible due to their main advantage of immunotolerance. However, some reports have claimed recently that aberrant gene expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogomiakova, Margarita E., Sekretova, Elizaveta K., Anufrieva, Ksenia S., Khabarova, Polina O., Kazakova, Anastasia N., Bobrovsky, Pavel A., Grigoryeva, Tatiana V., Eremeev, Artem V., Lebedeva, Olga S., Bogomazova, Alexandra N., Lagarkova, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088155/
https://www.ncbi.nlm.nih.gov/pubmed/37038186
http://dx.doi.org/10.1186/s13287-023-03308-5
_version_ 1785022510568308736
author Bogomiakova, Margarita E.
Sekretova, Elizaveta K.
Anufrieva, Ksenia S.
Khabarova, Polina O.
Kazakova, Anastasia N.
Bobrovsky, Pavel A.
Grigoryeva, Tatiana V.
Eremeev, Artem V.
Lebedeva, Olga S.
Bogomazova, Alexandra N.
Lagarkova, Maria A.
author_facet Bogomiakova, Margarita E.
Sekretova, Elizaveta K.
Anufrieva, Ksenia S.
Khabarova, Polina O.
Kazakova, Anastasia N.
Bobrovsky, Pavel A.
Grigoryeva, Tatiana V.
Eremeev, Artem V.
Lebedeva, Olga S.
Bogomazova, Alexandra N.
Lagarkova, Maria A.
author_sort Bogomiakova, Margarita E.
collection PubMed
description BACKGROUND: Dozens of transplants generated from pluripotent stem cells are currently in clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible due to their main advantage of immunotolerance. However, some reports have claimed recently that aberrant gene expression followed by proteome alterations and neoantigen formation can result in iPSCs recognition by autologous T-cells. Meanwhile, the possibility of NK-cell activation has not been previously considered. This study focused on the comparison of autologous and allogeneic immune response to iPSC-derived cells and isogeneic parental somatic cells used for reprogramming. METHODS: We established an isogeneic cell model consisting of parental dermal fibroblasts, fibroblast-like iPSC-derivatives (iPS-fibro) and iPS-fibro lacking beta-2-microglobulin (B2M). Using the cells obtained from two patients, we analyzed the activation of autologous and allogeneic T-lymphocytes and NK-cells co-cultured with target cells. RESULTS: Here we report that cells differentiated from iPSCs can be recognized by NK-cells rather than by autologous T-cells. We observed that iPS-fibro elicited a high level of NK-cell degranulation and cytotoxicity, while isogeneic parental skin fibroblasts used to obtain iPSCs barely triggered an NK-cell response. iPSC-derivatives with B2M knockout did not cause an additional increase in NK-cell activation, although they were devoid of HLA-I, the major inhibitory molecules for NK-cells. Transcriptome analysis revealed a significant imbalance of ligands for activating and inhibitory NK-cell receptors in iPS-fibro. Compared to parental fibroblasts, iPSC-derivatives had a reduced expression of HLA-I simultaneously with an increased gene expression of major activating ligands, such as MICA, NECTIN2, and PVR. The lack of inhibitory signals might be due to insufficient maturity of cells differentiated from iPSCs. In addition, we showed that pretreatment of iPS-fibro with proinflammatory cytokine IFNγ restored the ligand imbalance, thereby reducing the degranulation and cytotoxicity of NK-cells. CONCLUSION: In summary, we showed that iPSC-derived cells can be sensitive to the cytotoxic potential of autologous NK-cells regardless of HLA-I status. Thus, the balance of ligands for NK-cell receptors should be considered prior to iPSC-based cell therapies. Trial registration Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03308-5.
format Online
Article
Text
id pubmed-10088155
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100881552023-04-12 iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors Bogomiakova, Margarita E. Sekretova, Elizaveta K. Anufrieva, Ksenia S. Khabarova, Polina O. Kazakova, Anastasia N. Bobrovsky, Pavel A. Grigoryeva, Tatiana V. Eremeev, Artem V. Lebedeva, Olga S. Bogomazova, Alexandra N. Lagarkova, Maria A. Stem Cell Res Ther Research BACKGROUND: Dozens of transplants generated from pluripotent stem cells are currently in clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible due to their main advantage of immunotolerance. However, some reports have claimed recently that aberrant gene expression followed by proteome alterations and neoantigen formation can result in iPSCs recognition by autologous T-cells. Meanwhile, the possibility of NK-cell activation has not been previously considered. This study focused on the comparison of autologous and allogeneic immune response to iPSC-derived cells and isogeneic parental somatic cells used for reprogramming. METHODS: We established an isogeneic cell model consisting of parental dermal fibroblasts, fibroblast-like iPSC-derivatives (iPS-fibro) and iPS-fibro lacking beta-2-microglobulin (B2M). Using the cells obtained from two patients, we analyzed the activation of autologous and allogeneic T-lymphocytes and NK-cells co-cultured with target cells. RESULTS: Here we report that cells differentiated from iPSCs can be recognized by NK-cells rather than by autologous T-cells. We observed that iPS-fibro elicited a high level of NK-cell degranulation and cytotoxicity, while isogeneic parental skin fibroblasts used to obtain iPSCs barely triggered an NK-cell response. iPSC-derivatives with B2M knockout did not cause an additional increase in NK-cell activation, although they were devoid of HLA-I, the major inhibitory molecules for NK-cells. Transcriptome analysis revealed a significant imbalance of ligands for activating and inhibitory NK-cell receptors in iPS-fibro. Compared to parental fibroblasts, iPSC-derivatives had a reduced expression of HLA-I simultaneously with an increased gene expression of major activating ligands, such as MICA, NECTIN2, and PVR. The lack of inhibitory signals might be due to insufficient maturity of cells differentiated from iPSCs. In addition, we showed that pretreatment of iPS-fibro with proinflammatory cytokine IFNγ restored the ligand imbalance, thereby reducing the degranulation and cytotoxicity of NK-cells. CONCLUSION: In summary, we showed that iPSC-derived cells can be sensitive to the cytotoxic potential of autologous NK-cells regardless of HLA-I status. Thus, the balance of ligands for NK-cell receptors should be considered prior to iPSC-based cell therapies. Trial registration Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-023-03308-5. BioMed Central 2023-04-11 /pmc/articles/PMC10088155/ /pubmed/37038186 http://dx.doi.org/10.1186/s13287-023-03308-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bogomiakova, Margarita E.
Sekretova, Elizaveta K.
Anufrieva, Ksenia S.
Khabarova, Polina O.
Kazakova, Anastasia N.
Bobrovsky, Pavel A.
Grigoryeva, Tatiana V.
Eremeev, Artem V.
Lebedeva, Olga S.
Bogomazova, Alexandra N.
Lagarkova, Maria A.
iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
title iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
title_full iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
title_fullStr iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
title_full_unstemmed iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
title_short iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors
title_sort ipsc-derived cells lack immune tolerance to autologous nk-cells due to imbalance in ligands for activating and inhibitory nk-cell receptors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088155/
https://www.ncbi.nlm.nih.gov/pubmed/37038186
http://dx.doi.org/10.1186/s13287-023-03308-5
work_keys_str_mv AT bogomiakovamargaritae ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT sekretovaelizavetak ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT anufrievaksenias ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT khabarovapolinao ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT kazakovaanastasian ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT bobrovskypavela ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT grigoryevatatianav ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT eremeevartemv ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT lebedevaolgas ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT bogomazovaalexandran ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors
AT lagarkovamariaa ipscderivedcellslackimmunetolerancetoautologousnkcellsduetoimbalanceinligandsforactivatingandinhibitorynkcellreceptors